2018-01-01 - The IGBA welcomes the Indian Pharmaceutical Alliance (IPA) to its membership. The IPA represents Indian research-based national pharmaceutical companies. This addition to the IGBA membership is significant in widening the IGBA representation, which now covers this important region.
June 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of a regulatory framework for biosimilar medicines in Europe through her 15 years of experience with the Biosimilar Medicines Group, a Medicines for Europe sector group. Ingrid has a wealth of international regulatory knowledge and business and scientific experience.
- European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World
- IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to Medicines
- IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly
- Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda